Related Experiment Video
Updated: Jun 13, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding
Matyas Pal Timari1,2, Attila Paczal1, Andras Herner1
1Servier Research Institute of Medicinal Chemistry, Záhony utca 7, Budapest H-1031, Hungary.
Abstract:
Evasion of apoptosis is a hallmark of cancer. Deregulation of BCL-XL, a member of the BCL-2 family of proteins, has been linked to the development of various tumor types. This study presents the design and synthesis of BCL-XL inhibitors with novel mono- and bicyclic cores. The new structural features were optimized to combine high binding efficiency with the opening of diverse novel vectors for additional modifications. The lead compounds exhibited picomolar affinities and significant cellular potency in the BCL-XL-dependent MOLT-4 cell line, which also translated into marked tumor growth inhibition in a xenograft study. These findings highlight the potential of BCL-XL inhibitors as therapeutic agents in cancer treatment by targeting the apoptotic intrinsic pathway.
Insights
Researchers developed novel BCL-XL inhibitors targeting cancer
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Evasion of apoptosis is a key characteristic of cancer development.
- Dysregulation of BCL-XL, a BCL-2 family protein, is implicated in various cancers.
Purpose of the Study:
- To design and synthesize novel BCL-XL inhibitors.
- To optimize inhibitors for high binding affinity and further modification.
- To evaluate their therapeutic potential in cancer treatment.
Main Methods:
- Chemical synthesis of novel mono- and bicyclic BCL-XL inhibitors.
- Assessment of binding affinities and cellular potency in BCL-XL-dependent cell lines.
- In vivo evaluation using xenograft tumor models.
Main Results:
- Novel inhibitors with unique mono- and bicyclic cores were synthesized.
- Lead compounds demonstrated picomolar binding affinities and potent cellular activity.
- Significant tumor growth inhibition was observed in xenograft studies.
Conclusions:
- The novel BCL-XL inhibitors show promise as therapeutic agents.
- Targeting the intrinsic apoptotic pathway via BCL-XL inhibition is a viable cancer treatment strategy.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019